{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Valproic Acid in the Treatment of Migraines

Activity Steps

Purpose of Activity

To provide information about the initial abortive treatment of patients with migraines and the use of valproic acid in these patients.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Explain the epidemiology, clinical presentation, and pathophysiology of migraines.
  2. Identify and discuss the medications commonly used in the treatment of migraines.
  3. Outline the use of valproic acid as initial abortive therapy in the treatment of migraines.
Price: $17.95


  • ANCC 1.5 CH / 1.5 APH
  • DC - BON 1.5 CH
  • FL - BON 1.5 CH
  • GA - BON 1.5 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Awarded Advanced Pharmacology Hours

Test Code: AENJ1020A
Published: Oct/Dec 2020
Expires: 12/2/2022
Required Passing Score: 13/18 (72%)
Authors: Brandy L. Brown, PharmD; Lauren K. Craycraft, PharmD; Stephanie Baker Justice, PharmD, BCPS